Stanford Graduate School of Business (USA)
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems - Teaching Note
Chess, R; Luthre, JTeaching Note SGSB-E489TN-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €0.00
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems
Chess, R; Luthre, JCase SGSB-E489-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €8.20
-
All Hands: A Tale of Two Term Sheets
Siegel; Robert; Beyer, Amy; Morales; AlessiaCase SGSB-E822-EEntrepreneurshipIn this case study, students will explore some of the differences and considerations that may emerge when entrepreneurs evaluate and choose between multiple financing offers from venture capital investors. The case follows the two founders of a fictional company, All Hands, as they raise a Series A financing round. The founders have received term sheets from two venture capital firms that differ not only in the valuation of the firm’s equity but ...Starting at €8.20